BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 29, 2001
 |  BioCentury  |  Emerging Company Profile

Cerylid: Purifying nature's stew

Deriving medicines from natural product extract libraries requires capabilities most companies are unwilling to build in-house, because of the complex chemical makeup of the extracts, according to Cerylid Biosciences Ltd. The company has a library of extracts from sources throughout Southeast Asia and has developed a miniaturized and automated process for identifying single molecules active in a biological screen from among the many compounds a single extract can contain.

The company is developing a product pipeline in oncology and inflammatory diseases, but also provides its capabilities to partners, screening its extract library against their targets.

Spun out of Amrad Corp. Ltd. (ASX:AML, Melbourne, Australia) early last year, Cerylid is the commercial partner in Australia's Cooperative Research Centre (CRC) for Discovery of Genes for Common Human Diseases. The company has the right of first refusal to license genes of therapeutic interest discovered by the CRC. Cerylid thus uses the CRC...

Read the full 733 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >